SCA
VNDA icon

Signpost Capital Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Signpost Capital Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-828,793
Closed -$11.9M – 17
2014
Q4 		$11.9M Sell
828,793
-745,559
-47% -$8.82M 4.38% 12
2014
Q3 		$16.3M Sell
1,574,352
-114,600
-7% -$1.5M 6.74% 5
2014
Q2 		$27.3M Buy
+1,688,952
New +$22.5M 10.37% 3

Other funds holding VNDA

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Signpost Capital Advisors's VNDA Position: Q1 2015 in Review

Signpost Capital Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q1 2015, closing a stake of 828,793 shares — an estimated $11.9M sold.

Signpost Capital Advisors first reported a position in VNDA in Q2 2014 and held it in 3 quarters. The position peaked at $27.3M in Q2 2014. 110 funds tracked by Wall St. Rank hold VNDA as of Q1 2015.

  • Signpost Capital Advisors reported no remaining Vanda Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Signpost Capital Advisors sold 828,793 Vanda Pharmaceuticals shares in Q1 2015, an estimated $11.9M.
  • Signpost Capital Advisors first reported a position in Vanda Pharmaceuticals in Q2 2014 and held it in 3 quarters.
  • Signpost Capital Advisors's Vanda Pharmaceuticals position peaked at $27.3M in Q2 2014.
  • 110 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2015.

Based on Signpost Capital Advisors's 13F filing for Q1 2015, filed 14 May 2015.